公开(公告)号：US20110294824A1

公开(公告)日：2011-12-01

申请号：US13100911

申请日：2011-05-04

申请人： Andreas BATHE ,  Bernd HELFERT ,  Steffen NEUENFELD ,  Heike KNIEL ,  Matthias BARTELS ,  Susanne RUDOLPH ,  Henning BÖTTCHER

发明人： Andreas BATHE ,  Bernd HELFERT ,  Steffen NEUENFELD ,  Heike KNIEL ,  Matthias BARTELS ,  Susanne RUDOLPH ,  Henning BÖTTCHER

IPC分类号： A61K31/496 ,  A61P25/24 ,  C07D405/14

CPC分类号： A61K31/496 ,  C07D405/12 ,  C07D405/14

摘要： The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.